Seqstant receives 1.8 million euros for the rapid detection of pathogens

Brandenburg Kapital invests in future technology: How Seqstant detects pathogens with a click and revolutionizes the treatment of serious infections.

The Teltow-based company Seqstant has completed a successful seed financing round of 1.8 million euros. This investment is aimed at driving forward the development and commercialization of its 'LiveGene' software, which makes it possible to identify pathogens with one click. Seqstant's software deals with pathogen diagnostics. It uses sequencing technology to identify pathogens from different patient samples. This innovative approach aims to treat serious infections faster and more precisely.

The investment was led by Brandenburg Kapital in collaboration with Impact Investments. Other investors such as the Venture League, the Berlin Business Angel Network SB21 and the HPI Seed Fund were also involved in this financing round.

In a world that is constantly facing new challenges from pathogens, we are determined to make our contribution to the health and safety of humanity.

Henri Knobloch, CEO and Co-Founder of Seqstant

Until now, it has taken up to six days to correctly identify pathogens using conventional methods, which means an enormous delay. Every year, over 120,000 people in Germany die from acute infections, costing the healthcare system over 10 billion euros. Seqstant's technology promises to drastically reduce this identification time. Henri Knobloch, CEO and Co-Founder of Seqstant, emphasized the company's mission to shape the future of pathogen diagnostics and contribute to the health and safety of humanity.

Hao Nam Nguyen, Investment Manager at Brandenburg Kapital, emphasized the importance of fast and accurate pathogen diagnostics in healthcare. He emphasized the high demand from laboratories for Seqstant's product, which enables real-time diagnosis and ensures optimal patient care.

Aiming for CE approval

Seqstant, founded in 2021 at the Hasso Plattner Institute, is now aiming for CE approval in 2023 following ISO13485 certification in 2022. Its aim is to improve medical diagnostics and thus optimize patient care. Brandenburg Kapital, as part of the Investment Bank of the State of Brandenburg (ILB), has been supporting Brandenburg companies through equity investments and investments since 1993. The focus is on the expansion of start-ups and small and medium-sized enterprises in the state of Brandenburg.

Through this financial support and the ongoing developments at Seqstant, this investment promises a significant step towards more efficient and precise pathogen diagnostics, which could ultimately improve the treatment of infections.